Leading Research into Head & Neck Cancer

Paving the way for new gene therapy

Full project name: Novel treatments for Cancer: Gene-Directed Enzyme Prodrug Therapy (GDEPT)

Tag: New treatment | Past Project

<strong>Tag:</strong> New treatment
Summary

The project utilises a new therapeutic technique known as Gene-directed enzyme prodrug therapy, or GDEPT.

In GDEPT, a gene is delivered to a target cancer cell by a virus. This gene then stimulates the production of a specific enzyme (Carboxypeptidase G2 CPG2) which has been shown to convert a non-toxic version of a drug- a ‘prodrug’- into a toxic cancer-killing drug at the site of the tumour.

Because the enzyme is selectively produced in the tumour cells, the effect of the toxic drug is only felt by the surrounding head and neck cancer cells, avoiding damage to healthy cells.

Work was done to optimize both the enzyme and the pro-drug and whilst Joshua helped engineer a virus to act as the deliverer of gene to cancer cells, known as a viral vector to, be used in GDEPT.

Publications

Help us beat cancer

Our life-saving work relies on the money you give us.

Donate now and together we can save more lives by beating cancer sooner.

Professor Caroline Springer
Professor Caroline Springer

Project type:
Project

Project Leader:
Professor Caroline Springer

Researcher:
Professor Caroline Springer

Commencement date:
Dr Joshua Tweedy

Length of project:
1 year

Funding provided:
£ 50,000

Funder:
-

Location:
The Institute of Cancer Research

Follow us

Get in touch

Call 020 3875 8991

Email info@oraclecancertrust.org

Registered-logos-grey

Oracle Cancer Trust is a registered charity in England and Wales (1142037). A company limited by guarantee. Registered company in England and Wales (7125497). Registered address: 10 Parsons Green House, 27 Parsons Green Lane, London SW6 4HH.